Lirum Therapeutics is an innovative clinical-stage biopharmaceutical company focused on treating debilitating diseases through the acquisition, development and commercialization of novel drug candidates. Its lead candidate, LX-101, is a novel targeted therapy directed to the IGF-1 receptor (IGF-1R) consisting of a proprietary, precision-engineered IGF-1 variant coupled to a therapeutic payload, which the company says provides a differentiated mechanism versus prior IGF-1R approaches. LX-101 has been evaluated in Phase 1 trials in patients with advanced, pretreated cancer, where it was reported to be well-tolerated and to demonstrate single-agent activity; no dose-limiting toxicity or maximum tolerated dose has been reached. Lirum intends to continue dose escalation and to optimize the administration schedule for LX-101. The company plans to focus development of LX-101 toward specific adult and pediatric oncology and autoimmune indications, including cancers with IGF-1/IGF-1R pathway alterations and thyroid eye disease (TED). Lirum recently completed a financing to support its clinical and preclinical activities and potential pipeline expansion.

Total raised

$7M

Funding rounds

1

Latest round

Equity

Latest activity

Feb 2023